{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:09:25Z","timestamp":1794344965843,"version":"4.9.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13075-015-0815-y","type":"journal-article","created":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T12:39:31Z","timestamp":1446467971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study"],"prefix":"10.1186","volume":"17","author":[{"name":"for the Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ei","family":"Sada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinari","family":"Takasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouichi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Muso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohko","family":"Murakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Arimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,2]]},"reference":[{"key":"815_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"J Jennette","year":"2013","unstructured":"Jennette J, Falk R, Bacon P, Basu N, Cid M, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1\u201311.","journal-title":"Arthritis Rheum."},{"key":"815_CR2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","volume":"66","author":"R Watts","year":"2007","unstructured":"Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66:222\u20137.","journal-title":"Ann Rheum Dis."},{"key":"815_CR3","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/rheumatology\/ker205","volume":"50","author":"S Fujimoto","year":"2011","unstructured":"Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford). 2011;50:1916\u201320.","journal-title":"Rheumatology (Oxford)"},{"key":"815_CR4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0","volume":"43","author":"RA Watts","year":"2000","unstructured":"Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000;43:414\u20139.","journal-title":"Arthritis Rheum."},{"key":"815_CR5","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/ar4550","volume":"16","author":"KE Sada","year":"2014","unstructured":"Sada KE, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther. 2014;16:R101.","journal-title":"Arthritis Res Ther."},{"key":"815_CR6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/rheumatology\/ken079","volume":"47","author":"LJ Liu","year":"2008","unstructured":"Liu LJ, Chen M, Yu F, Zhao MH, Wang HY. Evaluation of a new algorithm in classification of systemic vasculitis. Rheumatology (Oxford). 2008;47:708\u201312.","journal-title":"Rheumatology (Oxford)"},{"key":"815_CR7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310\u20137.","journal-title":"Ann Rheum Dis."},{"key":"815_CR8","doi-asserted-by":"crossref","unstructured":"Ntatsaki E, Carruthers D, Chakravarty K, D'Cruz D, Harper L, Jayne D, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014.","DOI":"10.1093\/rheumatology\/ket445"},{"key":"815_CR9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/ndt\/6.8.531","volume":"6","author":"M Haubitz","year":"1991","unstructured":"Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM. Cyclophosphamide pulse therapy in Wegener's granulomatosis. Nephrol Dial Transplant. 1991;6:531\u20135.","journal-title":"Nephrol Dial Transplant."},{"key":"815_CR10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/qjmed\/90.6.401","volume":"90","author":"D Adu","year":"1997","unstructured":"Adu D, Pall A, Luqmani RA, Richards NT, Howie AJ, Emery P, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM. 1997;90:401\u20139.","journal-title":"QJM."},{"key":"815_CR11","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","volume":"40","author":"L Guillevin","year":"1997","unstructured":"Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 1997;40:2187\u201398.","journal-title":"Arthritis Rheum."},{"key":"815_CR12","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/s10165-011-0525-5","volume":"22","author":"S Ozaki","year":"2012","unstructured":"Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol. 2012;22:394\u2013404.","journal-title":"Mod Rheumatol."},{"key":"815_CR13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.2006.062711","volume":"66","author":"B Hellmich","year":"2007","unstructured":"Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66:605\u201317.","journal-title":"Ann Rheum Dis."},{"key":"815_CR14","unstructured":"ICH Steering Committee. ICH harmonized tripartite guidline. Clinical safety data management: definitions and standards for expedited reporting; 1994."},{"key":"815_CR15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3899\/jrheum.130602","volume":"41","author":"S Furuta","year":"2014","unstructured":"Furuta S, Chaudhry AN, Hamano Y, Fujimoto S, Nagafuchi H, Makino H, et al. Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol. 2014;41:325\u201333.","journal-title":"J Rheumatol."},{"key":"815_CR16","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1002\/art.34562","volume":"64","author":"S Lionaki","year":"2012","unstructured":"Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64:3452\u201362.","journal-title":"Arthritis Rheum."},{"key":"815_CR17","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1002\/art.23800","volume":"58","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008;58:2908\u201318.","journal-title":"Arthritis Rheum."},{"key":"815_CR18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10157-012-0651-1","volume":"17","author":"K Sugiyama","year":"2013","unstructured":"Sugiyama K, Sada KE, Kurosawa M, Wada J, Makino H. Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. Clin Exp Nephrol. 2013;17:51\u20138.","journal-title":"Clin Exp Nephrol."},{"key":"815_CR19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36\u201344.","journal-title":"N Engl J Med."},{"key":"815_CR20","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"K Groot de","year":"2009","unstructured":"de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670\u201380.","journal-title":"Ann Intern Med."},{"key":"815_CR21","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2215\/CJN.01020113","volume":"8","author":"AA Joode de","year":"2013","unstructured":"de Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol. 2013;8:1709\u201317.","journal-title":"Clin J Am Soc Nephrol."},{"key":"815_CR22","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1046\/j.1523-1755.2002.00605.x","volume":"62","author":"HA Hauer","year":"2002","unstructured":"Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002;62:1732\u201342.","journal-title":"Kidney Int."},{"key":"815_CR23","doi-asserted-by":"crossref","unstructured":"Li ZY, Chang DY, Zhao MH, Chen M. Predictors of treatment resistance and relapse in ANCA-associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheumatol. 2014;66:1920-6.","DOI":"10.1002\/art.38621"},{"key":"815_CR24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2215\/CJN.05610611","volume":"7","author":"JG McGregor","year":"2012","unstructured":"McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012;7:240\u20137.","journal-title":"Clin J Am Soc Nephrol."},{"key":"815_CR25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","volume":"64","author":"M Walsh","year":"2012","unstructured":"Walsh M, Flossmann O, Berden A, Westman K, Hoglund P, Stegeman C, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:542\u20138.","journal-title":"Arthritis Rheum."},{"key":"815_CR26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3899\/jrheum.110705","volume":"39","author":"T Wada","year":"2012","unstructured":"Wada T, Hara A, Arimura Y, Sada KE, Makino H. Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. J Rheumatol. 2012;39:545\u201351.","journal-title":"J Rheumatol."},{"key":"815_CR27","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","volume":"62","author":"M Walsh","year":"2010","unstructured":"Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken). 2010;62:1166\u201373.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"815_CR28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/ard.2008.088302","volume":"68","author":"C Charlier","year":"2009","unstructured":"Charlier C, Henegar C, Launay O, Pagnoux C, Berezne A, Bienvenu B, et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis. 2009;68:658\u201363.","journal-title":"Ann Rheum Dis."},{"key":"815_CR29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","volume":"74","author":"J Robson","year":"2015","unstructured":"Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P, et al. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74:177\u201384.","journal-title":"Ann Rheum Dis."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0815-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T05:35:19Z","timestamp":1567316119000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.com\/content\/17\/1\/305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["815"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0815-y","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,2]]},"article-number":"305"}}